Introduction
Myeloproliferative neoplasms (MPNs) constitute a group of diseases associated with increased production of mature myeloerythroid cells and/or platelets. Besides chronic myeloid leukemia, which is driven by the BCR-ABL fusion gene, the three most prevalent diseases in MPNs are polycythemia vera, essential thrombocythemia, and primary myelofibrosis. An acquired somatic mutation in the tyrosine kinase JAK2 gene resulting in a valine-to-phenylalanine substitution at position 617 (JAK2V617F) is most commonly seen in patients with BCR-ABL -MPN, which leads to constitutive activation of JAK-STAT pathway. [1] [2] [3] [4] [5] One of the most dismal complications in MPNs is their transformation to acute myeloid leukemia (AML), which is seen in 4% to 8% of patients with polycythemia vera or essential thrombocythemia within 20 years and in 8% to 23% of primary myelofibrosis patients in the first 10 years. [6] [7] [8] [9] [10] Although the JAK2V617F mutation is critically involved in the pathogenesis of MPNs, as verified in different murine MPN models, the mutation alone cannot induce leukemia in those models. [11] [12] [13] [14] [15] [16] [17] [18] Recent studies have identified that acquisition of several gene alterations, including ASXL1, RUNX1, TET2, DNMT3A, IDH1/2, and TP53, is associated with leukemic transformations. [19] [20] [21] [22] [23] [24] [25] However, the fundamental mechanism involved in the increased risk for accumulation of genetic aberrations in MPNs remains to be elucidated. In addition to genotoxic agents used for treatment of MPNs, 26, 27 some MPN-intrinsic factors should contribute to leukemic transformation, considering that the event also occurs in treatment-naïve patients. 8 Curiously, the AML cells transformed from JAK2V617F
1 MPNs frequently lack the JAK2 mutation: 3 of 4, 9 of 17, and 9 of 16 patients developed JAK2 wild-type (WT) leukemia after JAK2-mutant MPNs in previous studies. [28] [29] [30] These results strongly indicate that the leukemia cells are derived from JAK2V617F
-clones coexisting with JAK2V617F 1 clones in MPN phase. Although one of the driving factors might be the JAK2V617F-mediated genetic instability associated with the hyper-recombination phenotype, 31 it cannot explain the emergence of JAK2V617F -leukemia. In this study, we investigated the pathogenesis underlying the risk for leukemic transformation from MPNs by using a mouse model induced by transplantation of JAK2V617F-transduced bone marrow cells; we found that JAK2V617F -clones within MPN bone marrow also accumulate DNA damage and could have increased risk for progressing to leukemia.
Methods Mice
In murine experiments, 8-to 10-week-old female C57BL/6 mice purchased from Japan SLC, Inc. (Shizuoka, Japan) were used. Trp53-knockout mice on a C57BL/6 background were obtained from RIKEN BRC (Tsukuba, Japan; Acc. No. CDB0001K). 32 Lcn2 knockout mice on a mixed 129/sv-C57BL/6 background were established as previously described. 33 WT littermates were used as controls. All animal experiments were approved by the University of Tokyo Ethics Committee for Animal Experiments.
Reagents and antibodies
JAK2 inhibitor ruxolitinib (INCB018424) was purchased from Adooq Bioscience (Irvine, CA) and used at 100 nM for in vitro analysis. For in vivo studies, mice were treated with the inhibitor at an oral dose of 125 mg/kg. N-acetyl-L-cysteine, deferoxamine mesylate, and nutlin-3 were from SigmaAldrich, and recombinant mouse and human lipocalin-2 were from R&D Systems. In the apoptosis assay, cells were stained with Annexin V-APC (BD Biosciences) and analyzed by flow cytometry. Intracellular reactive oxygen species (ROS) production was measured with the 29,79-dichlorodihydrofluorescein diacetate fluorescent dye (Life Technologies). Cells were incubated with 35 mM 29,79-dichlorodihydrofluorescein diacetate for 30 minutes at 37°C. Antibodies used for experiments are summarized in supplemental Table 1 available at the Blood Web site.
Retrovirus production and bone marrow transplantation assays
Plat-E packaging cells were transiently transfected with each retrovirus vector, and the supernatants were used for infection. The MPN mouse model was established by transducing pGCDNsam-JAK2V617F-internal ribosome entry site (IRES)-enhanced green fluorescent protein (EGFP) into c-Kit 1 bone marrow cells and injecting the green fluorescent protein (GFP)-positive cells into lethally irradiated (9.5 Gy) mice. Murine hematopoietic cell line 32D cells were transduced with pGCDNsam-JAK2V617F-IRES-EGFP, pGCDNsam-WT-JAK2-IRES-EGFP, or the empty EGFP vector and hemagglutinin-tagged pMYs-neo-murine Mpl. 34 For analyzing ROS levels, Kusabira-Orange-containing plasmids instead of EGFP were transduced.
Flow cytometry
Each fraction from normal or MPN bone marrow was isolated by using a FACSAria II cell sorter (Becton Dickinson). Analysis was performed with FlowJo software (Treestar, Ashland, OR).
Immunofluorescence analysis
Immunofluorescence staining of cells was performed as previously described. 35 Briefly, cells were fixed with 3.7% formaldehyde in phosphatebuffered saline, permeabilized by treatment with 0.2% Triton-X, and blocked with 1% bovine serum albumin in phosphate-buffered saline. The slides were incubated with primary antibodies at 4°C, followed by incubation with Alexa Fluor 488 goat anti-mouse immunoglobulin G (IgG; Life Technologies) and TO-PRO3 (Molecular Probes). Because the transplanted bone marrow cells expressed GFP, Alexa Fluor 647 goat anti-mouse IgG (Life Technologies) and 4,6 diamidino-2-phenylindole were used for analysis. Fluorescence images were captured with an Olympus FluoView FV10i confocal microscope. The mean intensity of intranuclear 8-hydroxy-2-deoxyguanosine was measured within a region of interest placed within the nucleus by using the Fluoview software. The background-subtracted fluorescence intensity was calculated in each cell, and the average intensity with standard deviation was calculated.
Immunoblotting
In each experiment, total-cell lysates were subjected to immunoblotting. Membranes were probed with the primary antibodies followed by horseradish peroxidase-labeled anti-mouse or anti-rabbit IgG antibodies (Santa Cruz Biotechnology). Detection was performed with Immunostar LD western blotting detection reagent (Wako) and an LAS-3000 image analyzer (FujiFilm).
Analysis of microarray data
We analyzed publicly available gene expression microarray data, including murine and human samples with accession numbers GSE21842 and GSE9827. A set of CEL files were downloaded from Gene Expression Omnibus and normalized by using the justRMA function from the affy package of Bioconductor. For screening of genes with elevated expression in JAK2V617F
1 cells compared with their normal counterparts, the expression values of individual genes were compared between groups by using the RankProd analysis, and the significantly elevated genes, as determined by false discovery rate ,0.05 in both expression data, were selected.
Quantitative real-time PCR
Quantitative real-time polymerase chain reaction (PCR) was carried out on the LightCycler480 system (Roche) by using SYBR Green reagents according to the manufacturer's instructions. The results were normalized to Gapdh levels. Relative expression levels were calculated by using the 2-DDCT method. 36 The primer sequences are summarized in supplemental Table 2 .
shRNA interference
Gene-specific short hairpin RNAs (shRNAs) were designed and cloned into pSIREN-RetroQ-ZsGreen vectors (supplemental Table 2 ). Control shRNA is a nonfunctional construct provided from Clontech. JAK2V617F
1 32D cells were transduced with each vector and purified by flow cytometry by using an fluorescein isothiocyanate filter on the basis of the difference in fluorescence intensity.
Measurement of lipocalin-2 levels
To obtain cell conditioned media (CM), 32D cells were cultured for 24 hours at a concentration of 1 3 10 6 cells per milliliter in RPMI medium with 10% fetal bovine serum and 10% WEHI-3B supernatant. Human bone marrow mononuclear cells were cultured in RPMI medium supplemented with 10% fetal bovine serum, 25 ng/mL of stem cell factor, and 10 ng/mL of interleukin-3 (IL-3), IL-6, and FMS-like tyrosine kinase-3. The culture supernatants were collected after 48 hours. The concentration of lipocalin-2 was measured with murine or human Lipocalin-2 ELISA Kit (R&D Systems) based on a 4-parameter logistic regression model generated from the standard dilution curve in each assay.
Luciferase assay
32D-JAK2V617F cells were transiently transfected with pGL4.14[luc2/ Hygro] with WT or mutant Lcn2 promoter fragments provided by Dr. M.R. Green. 37 The cells were harvested 48 hours after transfection and assayed for luciferase activity in duplicate with a dual luciferase kit (Piccagene; TOYO B-Net) according to the manufacturer's protocol.
Measurement of intracellular iron levels
Intracellular iron concentration was measured by using an iron assay kit according to the manufacturer's instructions (Metallo assay; AKJ Global Technology). Total-cell lysates collected from 32D cells were used for measurements after the addition of 1M hydrochloric acid at a final concentration of 0.05 M. Intracellular iron concentration was corrected with the total amount of protein and described as picograms per microgram of protein.
Statistical analysis
Statistical significance of differences between different groups was assessed with a 2-tailed unpaired or paired Student t test. Differences were considered statistically significant at a P value of less than .05.
Study approval
Patient-derived bone marrow cells and serum were obtained from the Department of Hematology and Oncology, The University of Tokyo Hospital, Tokyo, Japan. The study was approved by the ethical committee of the University of Tokyo, and written informed consent was obtained from all patients whose samples were collected in accordance with the Declaration of Helsinki.
Results

Normal hematopoietic cells within JAK2V617F-induced MPNs are susceptible to DNA damage
To examine the accumulation of DNA damage in the bone marrow cells of JAK2V617F-induced MPNs, we analyzed a murine model of JAK2V617F
1 MPNs ( Figure 1A ). MPN bone marrow cells contained both GFP 1 and GFP -fractions, and we confirmed that JAK2 phosphorylation was enhanced only in GFP 1 fractions (supplemental Figure 1A) . By using this MPN model, we evaluated the accumulation of DNA damage by immunofluorescence staining of gH2AX. We analyzed all the bone marrow cells 2 months after transplantation to exclude not only the stress of transplantation that may induce ROS and DNA damage effects but also the age-related changes. Lineage Next, we were interested in whether the DNA damage response observed in GFP -cells within MPN bone marrow is caused through the microenvironment of MPN bone marrow, or directly induced by JAK2V617F 1 cells in a paracrine manner. To test these hypotheses in vitro, murine myeloid cell line 32D cells were retrovirally transduced with JAK2V617F (JAK2V617F-32D), WT JAK2 (JAK2WT-32D), or GFP empty vector (EV-32D). Murine Mpl was also introduced into them as a homodimeric type I receptor, which is necessary for cytokine-independent JAK-STAT signaling activation mediated by JAK2V617F in 32D cells. 38 As previously described, the cells with coexpression of JAK2V617F and Mpl acquired constitutive activation of the JAK-STAT pathway (supplemental Figure 2A ). To assess the paracrine effects induced by JAK2V617F clones, the parental 32D cells were cultured with the media conditioned by JAK2V617F-32D, JAK2WT-32D, or EV-32D and assessed for gH2AX foci formation ( Figure 2A) . As with the data we obtained in the murine MPN model, exposure of parental 32D cells to the CM derived from JAK2V617F-32D led to significant increase of gH2AX foci formation ( Figure 2B and supplemental Figure 2B ) and intracellular ROS levels ( Figure 2C ). Furthermore, the 32D cells cultured in JAK2V617F-CM showed decreased proliferation compared with the control ( Figure 2D ). When N-acetyl-L-cysteine was added into the JAK2V617F-CM, the phenotypes reverted to normal. Consistent with ROS accumulation, 32D cells treated with JAK2V617F-CM showed elevated levels of 8-hydroxy-2-deoxyguanosine ( Figure 2E and supplemental Figure 2C ). We further evaluated other types of DNA damage: immunoblotting of XPA for base or nucleotide excision repair against single-stranded DNA damage, and immunofluorescence staining for cyclobutane pyrimidine dimer formation, which did not show significant changes among samples (supplemental Figure 2D-E) . Collectively, these results suggest that JAK2V617F
1 clones confer oxidative stressinduced DNA damage to coexisting normal cells via a paracrine mechanism independent of bone marrow microenvironment, and thereafter, the damaged normal hematopoietic cells activate a DNA damage response and suppress their proliferation.
Enhanced secretion of lipocalin-2 by JAK2V617F-harboring cells induces oxidative DNA damage in neighboring cells
Then, we conducted a search for the responsible factors associated with JAK2V617F-induced paracrine DNA damage. As a screening, we thoroughly investigated the genes with an increased expression in JAK2V617F 1 hematopoietic cells compared with their normal counterparts through analysis of both murine and human gene expression profiles (GSE21842 and GSE9827; Figure 3A ). In total, 21 genes were commonly upregulated in JAK2V617F 1 cells, among which we focused on 8 genes encoding soluble factors as candidates for paracrine signaling associated with DNA damage. We confirmed by quantitative PCR that 6 of the 8 genes were indeed highly expressed in JAK2V617F-32D cells compared with EV-32D cells ( Figure 3B ). For individually assessing the influence of these genes on paracrine DNA damage, we designed shRNA targeting each of them (supplemental Figure 3A) , transduced it into JAK2V617F-32D cells, and tested the change in DNA damage response ( Figure 3C and supplemental Figure 3B ). First, for the purpose of screening candidate genes, we evaluated the growth-inhibiting effects of JAK2V617F-CM as a result of oxidative DNA damage. As shown in Figure 3D , only when shRNA against Lcn2 was transduced into JAK2V617F-32D cells was the growth-inhibiting effect of the JAK2V617F-CM clearly cancelled. Similar results were also observed in another shRNA targeting Lcn2 (supplemental Figure 3C) . Before further exploring the influence of Lcn2 knockdown on JAK2V617F
1 cells, we confirmed that lipocalin-2 is significantly enriched in JAK2V617F-CM, and the knockdown of Lcn2 or treatment with JAK2 inhibitor ruxolitinib reduced the concentration of lipocalin-2 in JAK2V617F-CM to almost the same level as that in EV-CM ( Figure 3E ). Previous studies have reported that the Lcn2 promoter region contains a consensus binding site for STAT5. 37 We examined the transcriptional activity of this site in JAK2V617F-32D cells and found that the existence of this sequence, but not the mutated one, significantly enhanced the promoter activity, indicating that the expression of Lcn2 is directly regulated by JAK-STAT signaling (supplemental Figure 3D) . Furthermore, plasma concentration of lipocalin-2 in JAK2V617F-induced MPN mice and the relative expression levels of Lcn2 in JAK2V617F-transduced bone marrow cells were much higher compared with levels in the controls ( Figure 3F and supplemental Figure 4A ). The lipocalin-2 levels in MPN mice were significantly reduced by treatment with JAK2 inhibitor (supplemental Figure 4B) . Next, we investigated the abundance of lipocalin-2 in patients with MPN. Although there was a considerable variation in serum levels of lipocalin-2 among the patients, the levels were significantly higher compared with those of controls ( Figure 3G ). In addition, MPN bone marrow cells secreted a significantly higher amount of lipocalin-2 than non-MPN control cells ( Figure 3H and supplemental Table 3 ).
Then, we directly examined the effect of lipocalin-2 on DNA damage induction. Importantly, the enhanced levels of gH2AX foci formation evoked by JAK2V617F-CM were normalized when Lcn2 was knocked down ( Figure 3I ). Moreover, intracellular ROS levels of parental 32D cells were also reduced when they were cultured in Lcn2-suppressed JAK2V617F-CM ( Figure 3J ). Collectively, these results indicate that lipocalin-2 abundantly secreted from JAK2V617F
1 clones should be associated with oxidative DNA damage induction into neighboring cells in a paracrine manner.
Lipocalin-2 induces oxidative DNA damage through intracellular iron overload
Next, we analyzed the mechanism of lipocalin-2 for triggering DNA damage response through intracellular ROS accumulation. We confirmed that exogenous treatment with recombinant lipocalin-2 led to significant elevation of intracellular ROS levels ( Figure 4A ). Because previous studies have reported that lipocalin-2 has a role of transporting iron inside the cells 39, 40 and that excessive intracellular iron promotes oxidative stress, 41 we examined the relationship between lipocalin-2 treatment and intracellular iron uptake in hematopoietic cells. We quantified iron concentration within total cell lysates of 32D cells with or without treatment with lipocalin-2. Interestingly, 32D cells exposed to lipocalin-2 had significantly higher levels of intracellular iron, and the effect was further enhanced with addition of FeSO 4 to the medium ( Figure 4B ). Consistent with the results, intracellular ROS levels enhanced by lipocalin-2 reverted to normal with cotreatment of iron-chelating agent deferoxamine ( Figure 4C ). These results indicate that the paracrine oxidative stress effects of lipocalin-2 are mediated by intracellular iron overload, and iron chelating agents are effective for normalizing the effect.
Lipocalin-2-induced DNA damage response is associated with p53 pathway activation
We further studied the response of normal hematopoietic cells to lipocalin-2-induced DNA damage. Treatment of 32D cells with JAK2V617F-32D CM significantly increased the rate of apoptosis ( Figure 5A ), which is consistent with decreased cellular proliferation by the CM (Figure 2E) . Moreover, the expression levels of proapoptotic genes such as Bax, Pmaip1, and Bbc3 were elevated in the JAK2V617F-CM-treated 32D cells ( Figure 5B ). Since these genes are regulated by p53, we analyzed its pathway activity and found that both total and phosphorylated p53 were elevated in JAK2V617F-CM-treated 32D cells ( Figure 5C ), suggesting that p53 pathway has been activated in the cells accompanied by DNA damage, which led to increased apoptosis of the severely damaged cells. Similarly, 32D cells and murine bone marrow cells showed increased levels of p53 and elevated apoptosis in response to lipocalin-2 ( Figure 5D-F) . In contrast, lipocalin-2 had no effect on proliferation against the p53-deficient cells ( Figure 5G ). These results demonstrate that lipocalin-2 induces p53 pathway activation against DNA damage in normal hematopoietic cells, which results in increased apoptosis and reduced cellular proliferation.
Lipocalin-2 induces growth advantage of JAK2V617F
1 cells over normal hematopoietic cells
We further investigated the autocrine effects of lipocalin-2 on JAK2V617F 1 cells themselves. First, we confirmed that both JAK2V617F-32D and EV-32D cells showed a similar increase in intracellular ROS levels upon treatment with lipocalin-2 ( Figure 6A ). In contrast with EV-32D cells, however, 32D-JAK2V617F cells escaped growth suppression when exposed to lipocalin-2 ( Figure 6B ). Moreover, JAK2V617F-32D cells showed no significant increase in apoptosis when incubated with lipocalin-2-enriched medium ( Figure 6C ), which contrasted with the data for control 32D cells ( Figure 5A ). To exclude the influence of autonomous lipocalin-2 secretion, we used bone marrow cells derived from lipocalin-2-deficient mice. When bone marrow c-Kit 1 cells transduced with JAK2V617F or EV were evaluated for their colony-forming capacity, lipocalin-2 reduced colony-forming capacity in EV-transduced cells, but not in JAK2V617F 1 cells ( Figure 6D ). We also confirmed that normal bone marrow cells showed decreased cell proliferation when cocultured with JAK2V617F-transduced Lcn2 1/1 bone marrow cells, whereas they proliferated normally when cocultured with JAK2V617F-transduced Lcn2 2/2 bone marrow cells ( Figure 6E ).
JAK2V617F
1 cells did not show increase in p53 when treated with lipocalin-2, which presented a sharp contrast with normal bone marrow cells ( Figure 6F ). Lipocalin-2 also reduced colony-forming capacity for human non-MPN bone marrow cells, but not for MPN cells ( Figure 6G ). We were then interested in how JAK2V617F 1 cells escaped from the growth-inhibitory effects of lipocalin-2. On the basis of a previous study showing that JAK2V617F 1 cells have elevated levels of MDM2, which destabilizes p53 and prevents its upregulation upon DNA damage, 42 we speculated that MDM2 is the key mediator that induces differences in proliferation. To investigate this hypothesis, we first confirmed that JAK2V617F-32D cells had increased protein level of MDM2 ( Figure 6H) . Moreover, when cotreated with the MDM2 inhibitor nutlin-3, lipocalin-2 also suppressed the proliferation of JAK2V617F-32D cells ( Figure 6I BLOOD
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Lcn2 were transplanted into sublethally irradiated mice ( Figure 7A ). Although JAK2V617F
1 cells with knockdown of Lcn2 were still able to repopulate in the recipient bone marrow, they showed significantly reduced engraftment compared with the control ( Figure 7B ). Collectively, these results show that lipocalin-2 secreted from JAK2V617F 1 MPN clones confers a relative growth advantage to themselves via suppression of normal hematopoietic cells.
Discussion
During out research, we studied pathogenesis underlying the increased risk for leukemogenesis in patients with MPNs. Of note, discussed. 29, 30 Although there was a report showing that TET2 mutation was precedent to JAK2 mutation, the TET2 mutation can also occur as a late event in other cases, suggesting that the order of mutation acquisition is not essential. 43, 44 In any case, further accumulation of genetic events after the MPN phase is required for leukemic transformation, and there should exist a mechanism for propelling the events in MPN. Our study suggests that lipocalin-2 could take a role as one of the accelerators in leukemogenesis through induction of DNA damage. Our finding is unique in that lipocalin-2 acts on neighboring normal cells in paracrine fashion. As for the mechanism of lipocalin-2-induced oxidative stress, we showed that it increased intracellular iron uptake, which led to intracellular ROS elevation. Iron overload is a major cause of oxidative stress in myelodysplastic syndrome patients, primarily as a result of regular transfusions. 45 Our results could provide promising strategies for reducing the risk for leukemic transformation from MPNs. There has also been some evidence that lipocalin-2 is associated with the induction of other proinflammatory cytokines such as tumor necrosis factor a and IL-1b, which might also be related to the DNA damage through enhancing intra-bone marrow inflammatory states. 46, 47 Further studies are required for elucidating an effect of lipocalin-2 in vivo. In addition to JAK2V617F, we showed that JAK2V617F -MPN cells with insertion mutations in calreticulin (CALR) also had increased secretory capacities for lipocalin-2, which is reasonable considering that those mutations induce constitutive activation of the JAK-STAT pathway. Conversely, although patients with MPN have an increased risk for leukemic transformation compared with the general population, cumulative incidence rate is still low during long-term follow-up. As indicated in our study, normal hematopoietic cells have a safeguarding mechanism against DNA damage in which the p53 pathway plays an essential role for preventing the emergence of aberrant clones. Indeed, TP53 mutation is seen in about 20% of the patients with post-MPN AML and is one of the most common mutations among them, 25, 30, 49 whereas the mutation is reported in approximately 10% of de novo AML patients, indicating an especially crucial role of the pathway in preventing leukemogenesis from MPNs. 50 Alternatively, increased DNA damage responses could result in an error in DNA repair and acquisition of aberrant mutations. Although there is some evidence that quiescent hematopoietic stem cells more often use error-prone nonhomologous end joining rather than homologous recombination for repairing DNA double-strand breaks, 51 they are considered to be vulnerable to acquiring mutations for DNA damage.
Another equally important aspect of lipocalin-2 secretion from JAK2V617F 1 cells is that it inhibits the growth of normal hematopoietic cells. Although lipocalin-2-mediated suppression of normal hematopoiesis has been reported in the BCR-ABL-induced murine chronic myeloid leukemia model, its precise mechanism remains to be elucidated. 52, 53 We hypothesized that the growth suppression resulted from the p53 pathway activation after DNA damage. Consistent with the concept, lipocalin-2 did not suppress proliferation of p53-deficient bone marrow cells. Interestingly, JAK2V617F 1 cells did not suffer from growth suppression by lipocalin-2 as in BCR-ABL 1 cells, which led to the relative growth advantage of the clones. These data explain how JAK2V617F 1 cells accomplish clonal expansion despite their impaired hematopoietic stem cell function. 16, 54 Therefore, blocking lipocalin-2 secretion is considered beneficial for preventing propagation of MPN clones.
Collectively, lipocalin-2 secreted from MPN clones leads to initiation of malignant clones through DNA damage accumulation and supports their proliferation via suppression of the surrounding clones. There have been several studies showing that JAK-STAT signaling pathway is upregulated in different types of cancers. 55, 56 Inhibition of the signaling cascade might contribute to the alleviation of genetic instability induced by the tumor microenvironment.
Authorship
Contribution: Y.K. designed research, performed experiments, analyzed data, and wrote the manuscript; A.Y. and T.T.-K. performed experiments on a murine JAK2V617F MPN model and performed the analysis for DNA damage; S. Arai designed research and analyzed data; T.S. and S. Akira helped perform experiments using Lcn2-knockout mice; and M.K. designed the research and supervised the entire project.
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Correspondence: Mineo Kurokawa, Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan; e-mail: kurokawa-tky@umin.ac.jp. 
